Navigation

corticotropin (HP Acthar Gel, Acthar Gel)

 

Classes: Corticosteroids

Dosing and uses of HP Acthar Gel, Acthar Gel (corticotropin)

 

Adult dosage forms and strengths

injectable solution

  • 80 units/mL

 

Verification of Adrenal Responsiveness

40-80 unit IM/SC q24-72hr

 

Acute Exacerbations of Multiple Sclerosis

80-120 unit IM qDay for 2-3 weeks may be administered

 

Nephrotic Syndrome

Induces diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

40-80 units IM/SC q1-3days

 

Other Indications & Uses

Diagnostic: Testing of adrenal cortex function

Therapeutic: As corticosteroids

Edematous State: Indicated to induce diuresis or remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis

Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)

Dermatologic Diseases: Severe erythema multiforme, Stevens-Johnson syndrome

Allergic States: Serum sickness

Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis; optic neuritis; chorioretinitis; anterior segment inflammation

Respiratory Diseases: Symptomatic sarcoidosis

Infantile spasms (West syndrome): Indicated as monotherapy for the treatment of infantile spasms in infants and children <2 years

 

Pediatric dosage forms and strengths

injectable solution

  • 80 unit/mL

 

Anti-Inflammatory/Immunosuppressant

0.8 unit/kg/day IM or 25 units/m²/day divided q12-24hr

 

Infantile Spasms (West Syndrome)

<2 years: 75 units/m² IM BID x2 weeks, THEN gradually taper over 2 weeks

Tapering schedule

  • 30 units/m² IM qAM for 3 days, THEN
  • 15 units/m² IM qAM for3 days, THEN
  • 10 units/m² IM qAM for 3 days, THEN
  • 10 units/m² every other morning for 6 days

 

Nephrotic Syndrome

Induces diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

<2 years: Safety and efficacy not established

≥2 years: 40-80 units IM/SC q1-3days

 

HP Acthar Gel, Acthar Gel (corticotropin) adverse (side) effects

Frequency not defined

Common

  • Edema, hypertension
  • Psychotic disorder
  • Disorder of skin
  • Hyperglycemia
  • Peptic ulcer disease
  • Immune hypersensitivity reaction
  • Muscle weakness

Serious

  • Cardiomegaly, congestive heart failure, necrotizing arteritis
  • Encephalitis due to human herpes simplex virus, relapse
  • Decreased body growth, Children
  • Pancreatitis
  • Thromboembolic disorder
  • Glaucoma

 

Warnings

Contraindications

Sensitivity to porcine proteins

IV administration is contraindicated; give only by IM or SC injection

Suspected congenital infections in infants

Live or live attenuated vaccines are contraindicated in patients receiving immunosuppressive doses of corticotropin

Scleroderma

Osteoporosis

Systemic fungal infections

Ocular herpes simplex

Recent surgery

Active/history of peptic ulcer

CHF, HTn

 

Cautions

Immunizations, diabetes, renal insufficiency, diverticulitis, myasthenia gravis, hypothyroidism, liver cirrhosis

Prolonged use in children will inhibit skeletal growth

Risks of: HTN; Na & water retention; hypokalemia; infections; cataracts & glaucoma

 

Pregnancy and lactation

Pregnancy category: C

Lactation: excretion in milk unknown; use with caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of HP Acthar Gel, Acthar Gel (corticotropin)

Half-Life: 15 min

 

Mechanism of action

Porcine ACTH, stimulates adrenocortical hormone production